NL-OMON29326招募中不适用
Towards optimizing infliximab therapyin severe sarcoidosis patients:personalized medicine.
St Antonius Hospital Nieuwegein0 个研究点目标入组 52 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 52
研究概览
简要总结
/A
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Patients diagnosed with sarcoidosis being treated with infliximab or with an indication for infliximab;
- •2. Capability of giving informed consent.
排除标准
- •1. Vaccination with live viral or bacterial vaccines within the previous 3 months, or with the last dose within the previous 3 months;
- •2. Active or untreated latent tuberculosis (by mantoux-Elispot/TBC-IGRA);
研究者
相似试验
已完成
不适用
Towards optimizing infliximab therapy in severe sarcoidosis patients: personalized medicineSarcoidosisNL-OMON39486Sint Antonius Ziekenhuis52
进行中（未招募）
1 期
Accelerated infliximab infusions in inflammatory bowel diseaseInflammatory bowel diseasesEUCTR2021-000570-28-FITampere University Hospital130
终止
不适用
Infliximab Accelerated Induction in Moderate to Severe Pediatric UCUlcerative ColitisNCT03209232Schneider Children's Medical Center, Israel10
尚未招募
不适用
Adjusting infliximab dose in patients with inflammatory bowel disease, based on blood levels.Inflammatory Bowel Disease, in remission with infliximab treatment.NL-OMON27672Erasmus MC Rotterdam40
已完成
4 期
Precision Dosing of Infliximab Versus Conventional Dosing of InfliximabInflammatory Bowel DiseaseNCT02453776Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)80